DiamiR Receives Patent Allowance for Rett MicroRNA Biomarker

The United States Patent and Trademark Office (USPTO) has issued an allowance for a patent submitted by DiamiR for methods the company developed that use microRNA (miRNA) as biomarkers of Rett syndrome and other neurodevelopmental diseases.  Notices of Allowance are issued by…

Anavex 2-73 Earns U.S. Patent for Neurodevelopmental Disorders, Including Rett Syndrome

The United States Patent and Trademark Office (USPTO) granted a patent to Anavex Life Sciences covering Anavex 2-73 (blarcamesine) as a potential therapy for neurodevelopmental disorders, including Rett syndrome. The patent (No. 10,507,196) is valid until at least 2037 and also covers methods of treatment based on…